Matt Van De Rijn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10778747/publications.pdf

Version: 2024-02-01

13099 14208 38,433 127 68 128 citations h-index g-index papers 129 129 129 41234 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Detection of MDM2 amplification by shallow whole genome sequencing of cell-free DNA of patients with dedifferentiated liposarcoma. PLoS ONE, 2022, 17, e0262272.	2.5	1
2	The immunoregulatory landscape of human tuberculosis granulomas. Nature Immunology, 2022, 23, 318-329.	14.5	110
3	Reproducible, high-dimensional imaging in archival human tissue by multiplexed ion beam imaging by time-of-flight (MIBI-TOF). Laboratory Investigation, 2022, 102, 762-770.	3.7	16
4	Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas. Cancer, 2021, 127, 2666-2673.	4.1	15
5	Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma. Npj Genomic Medicine, 2021, 6, 30.	3.8	8
6	Atlas of clinically distinct cell states and ecosystems across human solid tumors. Cell, 2021, 184, 5482-5496.e28.	28.9	116
7	CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via inÂvivo dependency mapping. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	6
8	A human lung tumor microenvironment interactome identifies clinically relevant cell-type cross-talk. Genome Biology, 2020, 21, 107.	8.8	33
9	PAX7 expression in sarcomas bearing the EWSR1-NFATC2 translocation. Modern Pathology, 2019, 32, 154-156.	5.5	10
10	Detection of Circulating Tumor DNA in Patients With Uterine Leiomyomas. JCO Precision Oncology, 2019, 3, 1-9.	3.0	5
11	A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis. Clinical Sarcoma Research, 2019, 9, 12.	2.3	51
12	Detection of SS18-SSX1/2 fusion transcripts in circulating tumor cells of patients with synovial sarcoma. Diagnostic Pathology, 2019, 14, 24.	2.0	10
13	Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs). Clinical Sarcoma Research, 2019, 9, 3.	2.3	26
14	Detection of Premalignant Gastrointestinal Lesions Using Surface-Enhanced Resonance Raman Scattering–Nanoparticle Endoscopy. ACS Nano, 2019, 13, 1354-1364.	14.6	40
15	Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma. Molecular Cancer Research, 2019, 17, 676-685.	3.4	30
16	Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma. Clinical Cancer Research, 2018, 24, 2688-2699.	7.0	45
17	Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma. Cell Stem Cell, 2018, 22, 414-427.e6.	11.1	61
18	Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway. Gynecologic Oncology, 2018, 149, 388-393.	1.4	21

#	Article	IF	CITATIONS
19	<i>GFPT2</i> -Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma. Cancer Research, 2018, 78, 3445-3457.	0.9	75
20	Tissue-Specific Expression of the Low-Affinity IgG Receptor, FcγRIIb, on Human Mast Cells. Frontiers in Immunology, 2018, 9, 1244.	4.8	28
21	Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies. Human Pathology, 2018, 82, 39-45.	2.0	2
22	Immunohistochemistry for PAX7 is a useful confirmatory marker for Ewing sarcoma in decalcified bone marrow core biopsy specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 765-769.	2.8	7
23	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications, 2017, 8, 14674.	12.8	53
24	EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. Modern Pathology, 2017, 30, 1312-1320.	5 . 5	69
25	Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas. JCI Insight, 2017, 2, .	5.0	15
26	CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. Journal of Clinical Investigation, 2016, 126, 2610-2620.	8.2	336
27	Mapping a multiplexed zoo of mRNA expression. Development (Cambridge), 2016, 143, 3632-3637.	2.5	198
28	Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Modern Pathology, 2016, 29, 582-590.	5 . 5	164
29	Giant Pulmonary Artery Aneurysm in a Patient With Marfan Syndrome and Pulmonary Hypertension. Circulation, 2016, 133, 1218-1221.	1.6	7
30	Extraskeletal Osteosarcoma of the Hand: The Role of Marginal Excision and Adjuvant Radiation Therapy. Hand, 2015, 10, 602-606.	1.2	6
31	Clinically Relevant Molecular Subtypes in Leiomyosarcoma. Clinical Cancer Research, 2015, 21, 3501-3511.	7.0	129
32	KIT Signaling Promotes Growth of Colon Xenograft Tumors inÂMice and Is Up-Regulated in a Subset of Human ColonÂCancers. Gastroenterology, 2015, 149, 705-717.e2.	1.3	35
33	Molecular subtyping of leiomyosarcoma with 3′ end RNA sequencing. Genomics Data, 2015, 5, 366-367.	1.3	6
34	Molecular pathological analysis of sarcomas using paraffinâ€embedded tissue: current limitations and future possibilities. Histopathology, 2014, 64, 163-170.	2.9	17
35	A Role for Versican in the Development of Leiomyosarcoma. Journal of Biological Chemistry, 2014, 289, 34089-34103.	3.4	33
36	Endoscopic molecular imaging of human bladder cancer using a CD47 antibody. Science Translational Medicine, 2014, 6, 260ra148.	12.4	124

#	Article	lF	Citations
37	Stromal signatures in endometrioid endometrial carcinomas. Modern Pathology, 2014, 27, 631-639.	5.5	23
38	A cell-intrinsic role for TLR2–MYD88 in intestinal and breast epithelia and oncogenesis. Nature Cell Biology, 2014, 16, 1238-1248.	10.3	106
39	Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nature Genetics, 2014, 46, 601-606.	21.4	142
40	Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Women's Health, 2014, 14, 102.	2.0	35
41	Secondary breast angiosarcoma and germ line BRCA mutations: discussion of genetic susceptibility. Journal of Radiation Oncology, 2013, 2, 331-335.	0.7	4
42	Modeling Clear Cell Sarcomagenesis in the Mouse: Cell of Origin Differentiation State Impacts Tumor Characteristics. Cancer Cell, 2013, 23, 215-227.	16.8	51
43	Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies. Science, 2013, 341, 88-91.	12.6	401
44	Breakpoint Analysis of Transcriptional and Genomic Profiles Uncovers Novel Gene Fusions Spanning Multiple Human Cancer Types. PLoS Genetics, 2013, 9, e1003464.	3.5	97
45	Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3501-3506.	7.1	44
46	Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Oncolmmunology, 2013, 2, e24452.	4.6	5
47	Stromal Responses among Common Carcinomas Correlated with Clinicopathologic Features. Clinical Cancer Research, 2013, 19, 5127-5135.	7.0	16
48	Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer. Breast Cancer Research, 2013, 15, R117.	5.0	14
49	Desktop Transcriptome Sequencing From Archival Tissue to Identify Clinically Relevant Translocations. American Journal of Surgical Pathology, 2013, 37, 796-803.	3.7	17
50	Flipping the script on macrophages in leiomyosarcoma. Oncolmmunology, 2012, 1, 1202-1204.	4.6	8
51	Three differentiation states risk-stratify bladder cancer into distinct subtypes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2078-2083.	7.1	232
52	Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers. Genome Biology, 2012, 13, R75.	9.6	221
53	ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. Journal of Pathology, 2012, 227, 223-233.	4.5	77
54	The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6662-6667.	7.1	1,255

#	Article	IF	CITATIONS
55	A Tri-Marker Proliferation Index Predicts Biochemical Recurrence after Surgery for Prostate Cancer. PLoS ONE, 2011, 6, e20293.	2.5	32
56	Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target. Journal of Pathology, 2011, 225, 574-582.	4.5	20
57	Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival. Science Translational Medicine, 2011, 3, 108ra113.	12.4	603
58	Comparative Profiling of Primary Colorectal Carcinomas and Liver Metastases Identifies LEF1 as a Prognostic Biomarker. PLoS ONE, 2011, 6, e16636.	2.5	56
59	SMURF1 Amplification Promotes Invasiveness in Pancreatic Cancer. PLoS ONE, 2011, 6, e23924.	2.5	44
60	DOG1 for the Diagnosis of Gastrointestinal Stromal Tumor (GIST): Comparison Between 2 Different Antibodies. Applied Immunohistochemistry and Molecular Morphology, 2010, 18, 333-337.	1.2	69
61	Gene expression profiling for the investigation of soft tissue sarcoma pathogenesis and the identification of diagnostic, prognostic, and predictive biomarkers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 141-151.	2.8	43
62	Gross genomic alterations and gene expression profiles of high- grade serous carcinoma of the ovary with and without BRCA1 inactivation. BMC Cancer, 2010, 10, 493.	2.6	7
63	Genomeâ€wide transcriptome analyses reveal p53 inactivation mediated loss of miRâ€34a expression in malignant peripheral nerve sheath tumours. Journal of Pathology, 2010, 220, 58-70.	4.5	106
64	Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature, 2010, 466, 133-137.	27.8	657
65	3′-End Sequencing for Expression Quantification (3SEQ) from Archival Tumor Samples. PLoS ONE, 2010, 5, e8768.	2.5	123
66	LC3-mediated fibronectin mRNA translation induces fibrosarcoma growth by increasing connective tissue growth factor. Journal of Cell Science, 2009, 122, 1441-1451.	2.0	13
67	Ano1 is a selective marker of interstitial cells of Cajal in the human and mouse gastrointestinal tract. American Journal of Physiology - Renal Physiology, 2009, 296, G1370-G1381.	3.4	320
68	The Macrophage Colony-Stimulating Factor 1 Response Signature in Breast Carcinoma. Clinical Cancer Research, 2009, 15, 778-787.	7.0	177
69	A compact VEGF signature associated with distant metastases and poor outcomes. BMC Medicine, 2009, 7, 9.	5.5	162
70	Other Targetable Sarcomas. Seminars in Oncology, 2009, 36, 358-371.	2.2	12
71	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology, 2009, 22, 393-402.	5. 5	241
72	Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14016-14021.	7.1	584

#	Article	IF	Citations
73	Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays. Human Pathology, 2009, 40, 1244-1251.	2.0	39
74	Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. American Journal of Pathology, 2009, 174, 2347-2356.	3.8	83
75	The fibromatosis signature defines a robust stromal response in breast carcinoma. Laboratory Investigation, 2008, 88, 591-601.	3.7	100
76	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. Modern Pathology, 2008, 21, 1413-1420.	5. 5	3
77	Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Modern Pathology, 2008, 21, 531-539.	5.5	71
78	A Systems Biology Approach to Anatomic Diversity of Skin. Journal of Investigative Dermatology, 2008, 128, 776-782.	0.7	78
79	Gene Expression Profiling of Breast Cancer. Annual Review of Pathology: Mechanisms of Disease, 2008, 3, 67-97.	22.4	66
80	Prognostic Significance of Macrophage Infiltration in Leiomyosarcomas. Clinical Cancer Research, 2008, 14, 1423-1430.	7.0	152
81	Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor <i>Early Growth Response 1</i> in Synovial Sarcoma. Cancer Research, 2008, 68, 4303-4310.	0.9	104
82	Genomic Profiling Identifies GATA6 as a Candidate Oncogene Amplified in Pancreatobiliary Cancer. PLoS Genetics, 2008, 4, e1000081.	3.5	94
83	hCAP-D3 Expression Marks a Prostate Cancer Subtype With Favorable Clinical Behavior and Androgen Signaling Signature. American Journal of Surgical Pathology, 2008, 32, 205-209.	3.7	25
84	A Novel Monoclonal Antibody Against DOG1 is a Sensitive and Specific Marker for Gastrointestinal Stromal Tumors. American Journal of Surgical Pathology, 2008, 32, 210-218.	3.7	399
85	Gene Expression Programs of Human Smooth Muscle Cells: Tissue-Specific Differentiation and Prognostic Significance in Breast Cancers. PLoS Genetics, 2007, 3, e164.	3.5	56
86	Placental S100 (S100P) and GATA3: Markers for Transitional Epithelium and Urothelial Carcinoma Discovered by Complementary DNA Microarray. American Journal of Surgical Pathology, 2007, 31, 673-680.	3.7	219
87	TLE1 as a Diagnostic Immunohistochemical Marker for Synovial Sarcoma Emerging From Gene Expression Profiling Studies. American Journal of Surgical Pathology, 2007, 31, 240-246.	3.7	313
88	Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides. American Journal of Surgical Pathology, 2007, 31, 970-976.	3.7	199
89	The Stanford Tissue Microarray Database. Nucleic Acids Research, 2007, 36, D871-D877.	14.5	80
90	Gene Expression Patterns in Pancreatic Tumors, Cells and Tissues. PLoS ONE, 2007, 2, e323.	2.5	86

#	Article	IF	Citations
91	A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Modern Pathology, 2007, 20, 467-473.	5. 5	121
92	GENETICS OF SOFT TISSUE TUMORS. Annual Review of Pathology: Mechanisms of Disease, 2006, 1, 435-466.	22.4	37
93	A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 690-695.	7.1	474
94	Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14842-14847.	7.1	264
95	TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Modern Pathology, 2005, 18, 1641-1648.	5.5	37
96	Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecologic Oncology, 2005, 96, 684-694.	1.4	100
97	The gene expression profile of extraskeletal myxoid chondrosarcoma. Journal of Pathology, 2005, 206, 433-444.	4.5	65
98	Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3738-3743.	7.1	934
99	The Retinoic Acid Synthesis Gene ALDH1a2 Is a Candidate Tumor Suppressor in Prostate Cancer. Cancer Research, 2005, 65, 8118-8124.	0.9	130
100	Familial Gastrointestinal Stromal Tumor Syndrome: Phenotypic and Molecular Features in a Kindred. Journal of Clinical Oncology, 2005, 23, 2735-2743.	1.6	146
101	A DNA microarray survey of gene expression in normal human tissues. Genome Biology, 2005, 6, R22.	9.6	198
102	Determination of Stromal Signatures in Breast Carcinoma. PLoS Biology, 2005, 3, e187.	5.6	180
103	Gene Expression in the Normal Adult Human Kidney Assessed by Complementary DNA Microarray. Molecular Biology of the Cell, 2004, 15, 649-656.	2.1	97
104	Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds. PLoS Biology, 2004, 2, e7.	5.6	824
105	Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene, 2004, 23, 7780-7790.	5.9	137
106	Novel endothelial cell markers in hepatocellular carcinoma. Modern Pathology, 2004, 17, 1198-1210.	5 . 5	78
107	Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma. Clinical Cancer Research, 2004, 10, 5367-5374.	7.0	2,393
108	Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 811-816.	7.1	1,175

#	Article	IF	Citations
109	The Novel Marker, DOG1, Is Expressed Ubiquitously in Gastrointestinal Stromal Tumors Irrespective of KIT or PDGFRA Mutation Status. American Journal of Pathology, 2004, 165, 107-113.	3.8	593
110	Apo D in Soft Tissue Tumors. American Journal of Surgical Pathology, 2004, 28, 1063-1069.	3.7	81
111	Tissue Microarray Validation of Epidermal Growth Factor Receptor and SALL2 in Synovial Sarcoma with Comparison to Tumors of Similar Histology. American Journal of Pathology, 2003, 163, 1449-1456.	3.8	133
112	Gene Expression Patterns and Gene Copy Number Changes in Dermatofibrosarcoma Protuberans. American Journal of Pathology, 2003, 163, 2383-2395.	3.8	142
113	Gene Expression Patterns in Renal Cell Carcinoma Assessed by Complementary DNA Microarray. American Journal of Pathology, 2003, 162, 925-932.	3.8	247
114	Endothelial cell diversity revealed by global expression profiling. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 10623-10628.	7.1	679
115	Gene Expression Patterns in Ovarian Carcinomas. Molecular Biology of the Cell, 2003, 14, 4376-4386.	2.1	302
116	Transcriptomes of Soft Tissue Tumors. , 2003, , 305-327.		0
117	Diversity, topographic differentiation, and positional memory in human fibroblasts. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12877-12882.	7.1	983
118	Tissue Microarrays Are an Effective Quality Assurance Tool for Diagnostic Immunohistochemistry. Modern Pathology, 2002, 15, 1374-1380.	5.5	143
119	Gene Expression Studies on Soft Tissue Tumors. American Journal of Pathology, 2002, 161, 1531-1534.	3.8	18
120	Software Tools for High-Throughput Analysis and Archiving of Immunohistochemistry Staining Data Obtained with Tissue Microarrays. American Journal of Pathology, 2002, 161, 1557-1565.	3.8	194
121	Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome. American Journal of Pathology, 2002, 161, 1991-1996.	3.8	494
122	Gene Expression Patterns in Human Liver Cancers. Molecular Biology of the Cell, 2002, 13, 1929-1939.	2.1	779
123	Molecular characterisation of soft tissue tumours: a gene expression study. Lancet, The, 2002, 359, 1301-1307.	13.7	537
124	Challenges in developing a molecular characterization of cancer. Seminars in Oncology, 2002, 29, 280-285.	2.2	10
125	Towards a novel classification of human malignancies based on gene expression patterns. Journal of Pathology, 2001, 195, 41-52.	4.5	265
126	Systematic variation in gene expression patterns in human cancer cell lines. Nature Genetics, 2000, 24, 227-235.	21.4	1,946

#	Article	IF	CITATIONS
127	Molecular portraits of human breast tumours. Nature, 2000, 406, 747-752.	27.8	13,397